XOMA (NASDAQ:XOMA) Receives New Coverage from Analysts at SVB Leerink

Stock analysts at SVB Leerink initiated coverage on shares of XOMA (NASDAQ:XOMA) in a research report issued on Monday, Briefing.com reports. The firm set an “outperform” rating and a $40.00 price target on the biotechnology company’s stock. SVB Leerink’s price target points to a potential upside of 57.42% from the company’s current price.

Separately, HC Wainwright reiterated a “buy” rating and set a $74.00 price target on shares of XOMA in a research note on Thursday.

XOMA Price Performance

Shares of NASDAQ:XOMA opened at $25.41 on Monday. The company has a market capitalization of $295.77 million, a P/E ratio of -6.29 and a beta of 0.58. The company’s 50-day moving average is $24.91 and its 200 day moving average is $20.48. The company has a debt-to-equity ratio of 1.34, a quick ratio of 8.68 and a current ratio of 8.68. XOMA has a fifty-two week low of $13.48 and a fifty-two week high of $27.00.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings data on Friday, March 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.13). XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. The company had revenue of $1.83 million during the quarter, compared to the consensus estimate of $1.01 million. On average, equities research analysts forecast that XOMA will post -1.73 earnings per share for the current year.

Hedge Funds Weigh In On XOMA

A hedge fund recently raised its stake in XOMA stock. Stonepine Capital Management LLC raised its holdings in shares of XOMA Co. (NASDAQ:XOMA) by 25.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 436,602 shares of the biotechnology company’s stock after purchasing an additional 87,203 shares during the period. XOMA accounts for about 2.0% of Stonepine Capital Management LLC’s holdings, making the stock its 12th largest holding. Stonepine Capital Management LLC owned about 3.80% of XOMA worth $6,152,000 at the end of the most recent quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.